Pipeline & Launch Brand Alerts — March 2026
We tracked 27 pharma news catalysts in March across approvals, new indication approvals, positive Phase 3 readouts and M&A. Here are the updates that matter most — led by infigratinib, iberdomide and QTORIN rapamycin gel.
At Athena BDA we publish a monthly newsletter for clients summarising the highest-priority FDA approvals and late-stage pipeline developments across pharma.
In March, we tracked 27 significant updates — including approvals, positive Phase 3 readouts, NDA submissions and M&A. Below are our top-priority selections as Hot Tips.
Hot Tip #1 — Infigratinib | BridgeBio
BridgeBio Pharma reported that its oral FGFR1-3 inhibitor infigratinib met the primary endpoint in a Phase 3 trial for children with achondroplasia, demonstrating a 2.1 cm/year improvement in annualized height velocity over placebo. The company plans to submit global regulatory filings in the second half of 2026.
Athena BDA insight: Priority Score 1 — our lead hot tip this month. BridgeBio is emerging as one of the most attractive small-pharma targets right now, with strong Attruby traction and three potential blockbuster assets in late-stage Phase 3. Analysts are now projecting $1–2B peak sales for infigratinib.
Hot Tip #2 — Iberdomide | Bristol Myers Squibb
The FDA granted Priority Review to Bristol Myers Squibb’s New Drug Application for iberdomide in combination with daratumumab and dexamethasone for relapsed or refractory multiple myeloma. The submission is supported by Phase 3 data and carries a target action date of August 17, 2026.
Athena BDA insight: Priority Score 1 — we are very bullish on iberdomide and the broader CELMoD division within BMS, which also includes mezigdomide in late-stage Phase 3 development. Combined, these assets carry peak sales estimates of around $3B, and BMS has already built out a sizeable CELMoD commercial team.
Hot Tip #3 — QTORIN 3.9% | Palvella
Palvella Therapeutics reported positive Phase 3 results for QTORIN 3.9% rapamycin gel in treating microcystic lymphatic malformations, meeting its primary endpoint with a statistically significant mean improvement on the mLM-IGA scale (p<0.001). The company plans to submit an NDA to the FDA in the second half of 2026.
Athena BDA insight: Priority Score 1 — analysts are projecting peak sales of around $1.6B for QTORIN following the positive Phase 3 readout. The commercial team is still relatively lean, but timing could be right to engage as Palvella ramps launch planning.
What else moved this month?
- A factor XIa inhibitor reduced the risk of ischemic stroke by 26% in patients following a noncardioembolic stroke or high-risk transient ischemic attack, with regulatory filings planned for 2026.
- The FDA approved the first all-oral, fixed-duration regimen for adults with previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma, reducing the risk of disease progression or death by 35% versus standard chemotherapy.
- An oral GLP-1 receptor agonist outperformed oral semaglutide in a Phase 3 diabetes trial, demonstrating a 2.2% reduction in HbA1c at 52 weeks, with filings in more than 40 countries and a U.S. decision expected in Q2 2026.
- The FDA approved a first-line therapy for HER2-mutant non-small cell lung cancer, granted just 44 days after filing via a priority review voucher, based on a 76% objective response rate.
Want the full March analysis — including drug names, sales projections, source links and commercial-readiness insight? It’s all available inside the Athena BDA Pharma Insights Hub.